Unexpected low incidence of vertebral fractures in heart transplant recipients: Analysis of bone turnover

Transplant International

Volumn 21, Issue 3, 2008, Pages 255-262

  Kerschan Schindl, Katharina ^a   Ruzicka, Margot ^a   Mahr, Stephane ^a   Paireder, Matthias ^a   Krestan, Christian ^a   Gleiss, Andreas ^a   Bieglmayer, Christian ^a   Fialka Moser, Veronika ^a   Pacher, Richard ^a   Grimm, Michael ^a   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biochemistry; Bone mineral density; Heart transplantation; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BIOCHEMICAL MARKER; CALCIUM; CEFAZOLIN; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OSTEOCALCIN; PARATHYROID HORMONE; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RECIPIENT; VERTEBRA FRACTURE;

BONE AND BONES; BONE DENSITY; FEMALE; HEART TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOCALCIN; POSTOPERATIVE COMPLICATIONS; SPINAL FRACTURES;

EID: 38849145679     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00598.x     Document Type: Article

References (46)

1. Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991 90 : 107.
2. Van Cleemput J, Daenen W, Nijs J, Geusens P, Dequeker J, Vanhaecke J. Timing and quantification of bone loss in cardiac transplant recipients. Transpl Int 1995 8 : 196.
3. Rico H, Revilla M, Hernandez ER, Villa LF, Del Buergo MA, Alonso AL. Age-and weight-related changes in total body bone mineral in men. Miner Electrolyte Metab 1991 17 : 321.
4. Grampp S, Genant HK, Mathur A, et al. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res 1997 12 : 697.
5. Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant 1994 13 : 116.
6. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metabol 1997 82 : 1497.
7. Thièbaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996 26 : 549.
8. Välimäki MJ, Kinnunen K, Tähtelä R, et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Ost Int 1999 10 : 128.
9. Kerschan-Schindl K, Strametz-Juranek J, Heinze G, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant 2003 22 : 843.
10. Zittermann A, Schleithoff S, Koerfer R. Markers of bone metabolism in congestive heart failure. Clin Chim Acta 2006 366 : 27.
11. Seibel MJ, Pols HPA. Clinical applications of biochemical markers of bone metabolism. Second edition. In : Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. New York : Academic Press, 2001 1293.
12. Zuckermann A, Bohdjalian A, Deviatko E, et al. The University of Vienna experience in heart transplantation. In : Cecke M, Terasaki PI, eds. Clin Transpl. Los Angeles : UCLA Immunogenetics Center, 2002 229.
13. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993 8 : 1137.
14. Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas 1980 2 : 109.
15. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981 53 : 58.
16. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994 9 : 1137.
17. Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester : John Wiley & Sons, 1999 : 199.
18. Shane E, Rodino MA, McMahon DJ, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998 17 : 1089.
19. Muchmore JS, Cooper DK, Schlegel V, Pribil A, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant 1992 11 : 959.
20. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994 96 : 35.
21. Shane E, Rivas M, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993 94 : 257.
22. Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996 81 : 1740.
23. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001 357 : 342.
24. Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisolone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 1992 11 : 950.
25. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004 350 : 767.
26. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 1997 137 : 209.
27. Nowacka-Cieciura E, Durlik M, Cieciura T, et al. Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients. Transplant Proc 2001 33 : 1273.
28. Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacolimus versus mycofenolate mofetil and tacolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005 37 : 1695.
29. Lavee J, Bar-Zohar D, Har-Zahav Y, et al. Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients: 6-year experience at the Sheba Medical Center. Transplant Proc 2000 32 : 737.
30. Norman DJ. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Sem Nephrol 1992 12 : 315.
31. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 1999 12 : 1260.
32. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Con Invest 2000 106 : 1229.
33. Schlosberg M, Movsovitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporine A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989 124 : 2179.
34. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporine-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988 123 : 2571.
35. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994 57 : 1231.
36. Mongeal A, Navvasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001 68 : 83.
37. Stempfle HU, Werner C, Siebert U, et al. The role of tac-rolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002 73 : 547.
38. Dissanayake IR, Goodman GR, Bowman AR, et al. Mycofenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998 65 : 275.
39. Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporine A-induced osteopenia in the rat. J Bone Miner Res 1995 10 : 132.
40. Torregrosa JV, Fuster D, Pedroso S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 2007 20 : 708.
41. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006 331 : 30.
42. Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone 1998 22 : 267.
43. Ramirez G, Narvarte J, Bittle PA, Ayers-Chastain C, Dean SE. Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron 1991 58 : 27.
44. Stempfle HU, Werner C, Echtler S, et al. Prevention of osteoporosis after cardiac transplantation. Transplantation 1999 68 : 523.
45. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003 87 : 179.
46. Kahan BD. Cyclosporine. N Engl J Med 1989 321 : 1725.